For individuals grappling with the debilitating effects of severe emphysema, a new minimally invasive procedure offering hope for improved breathing and quality of life is now available. Bronchoscopic lung volume reduction using thermal vapour ablation (BTVA), is being implemented at the Thoraxzentrum Münnerstadt in Germany, adding to their existing repertoire of advanced lung treatments. This innovative approach provides a crucial alternative for patients who may not be suitable candidates for other less invasive methods, such as valve implantation.
Emphysema, a chronic lung condition primarily caused by smoking, progressively damages the air sacs (alveoli) in the lungs, leading to shortness of breath and reduced lung function. BTVA aims to address this by carefully delivering precisely controlled bursts of steam to the most damaged areas of the lungs. This induces a targeted shrinkage of the affected tissue, effectively reducing the overall lung volume and allowing the remaining healthy tissue to function more efficiently. The procedure is performed bronchoscopically, meaning it’s accessed through the airways using a flexible tube with a camera, minimizing invasiveness compared to traditional surgical options.
How Thermal Vapour Ablation Works
The BTVA procedure utilizes a system, such as the InterVapor® system, to deliver thermal vapour directly to targeted lung segments. According to information from the Thoraxklinik Heidelberg, the steam creates a controlled inflammatory reaction, leading to the desired volume reduction. Crucially, the process doesn’t involve the placement of any foreign materials within the lungs, and initial studies suggest a relatively low complication rate. The precision of the technique allows for segment-specific treatment, minimizing impact on healthy lung tissue. This contrasts with earlier lung volume reduction techniques that were more broadly applied.
The introduction of BTVA at the Thoraxzentrum Münnerstadt was spearheaded by Bernd Seese, Chief Physician of Pneumology, who received specialized training in the technique at the Klinik Floridsdorf in Vienna. As reported by infranken.de, Seese emphasized the significance of expanding treatment options for patients with severe emphysema in the region.
The BENTO Study: Evaluating Long-Term Efficacy
The Thoraxzentrum is actively participating in the BENTO study, a multi-center, randomized controlled trial investigating the effectiveness and patient-centeredness of thermal vapour ablation in the German healthcare system. The BENTO study, formally titled “Bronchoskopische Lungenvolumenreduktion beim schweren Lungenemphysem mittels Thermoablation” (Bronchoscopic Lung Volume Reduction in Severe Emphysema by Thermoablation), was initiated at the request of the Gemeinsamer Bundesausschuss (G-BA), the German Federal Joint Committee. Details of the study are available on the Thoraxklinik Heidelberg website.
The BENTO study is designed to rigorously assess the benefits of BTVA compared to standard care. Participants with COPD and upper lobe-predominant emphysema with incomplete fissures are enrolled. Patients are randomly assigned to receive BTVA in addition to standard therapy or to initially receive only standard therapy, with BTVA delayed by nine months. The study aims to provide robust evidence regarding the long-term impact of BTVA on lung function, quality of life, and overall health outcomes. The study protocol, published in BMJ Open, details the study design and objectives.
Who is a Suitable Candidate for BTVA?
According to the Thoraxklinik Heidelberg, ideal candidates for BTVA typically include patients with COPD and emphysema primarily affecting the upper lobes of the lungs, with incomplete fissures. Individuals with significant limitations in their physical capacity, low diffusion capacity, or those who have previously undergone lung volume reduction procedures are generally not considered suitable. The procedure is not a cure for emphysema, but rather aims to alleviate symptoms, improve exercise tolerance, and enhance overall quality of life.
The potential benefits of BTVA include a reduction in shortness of breath and an improvement in the ability to perform daily activities. The procedure is designed to be less invasive than traditional surgical options, potentially leading to a faster recovery time and fewer complications. However, as with any medical procedure, there are potential risks and benefits that should be carefully discussed with a qualified healthcare professional.
Expanding Access to Advanced Lung Care
The introduction of BTVA at the Thoraxzentrum Bezirk Unterfranken, located on the Michelsberg, underscores the center’s commitment to providing cutting-edge care for patients with lung diseases. The center offers a comprehensive range of services for the diagnosis and treatment of all types of pneumological conditions. Stefanie Dörfner, Operations Manager of the Thoraxzentrum Bezirk Unterfranken, stated that the implementation of BTVA positions the center for continued success in the future.
Stefan Funk, District President of the Unterfranken district, highlighted the specialized expertise available within the district’s facilities, emphasizing the Thoraxzentrum Münnerstadt’s pioneering role in modern lung medicine. The center’s participation in the BENTO study further solidifies its position as a leading center for research and innovation in the field of pulmonary care.
The BENTO study is currently recruiting participants. Individuals interested in learning more about the study and potential eligibility criteria are encouraged to contact the Thoraxklinik Heidelberg or the participating clinics directly. The study is expected to provide valuable insights into the long-term benefits and risks of BTVA, ultimately informing clinical practice and improving the care of patients with severe emphysema.
The ongoing research and implementation of innovative procedures like BTVA represent a significant step forward in the treatment of emphysema, offering renewed hope for individuals struggling with this debilitating condition. As the BENTO study progresses, further data will emerge to refine patient selection criteria and optimize treatment protocols, ultimately maximizing the benefits of this promising new therapy.
The next major milestone for the BENTO study is the completion of patient enrollment and the subsequent analysis of the collected data, expected in late 2026 or early 2027. For more information about emphysema and available treatment options, consult with a qualified pulmonologist or visit the websites of reputable medical organizations such as the American Lung Association or the European Respiratory Society. Share your thoughts and experiences with lung health in the comments below.